Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Revenues Double in H1

NEW YORK (GenomeWeb) – Horizon Discovery Group reported on Monday that its total revenues as reported for the first half of 2018 more than doubled thanks to a significant contribution from its Dharmacon business and an increased reach into the US market.

For the six months ended June 30, the gene editing and gene modulation technologies company reported total revenues of £25.1 million ($33.0 million), up 107 percent from £12.1 million in the first half of 2017. On a constant currency basis, revenues rose 126 percent to £27.3 million.

H1 revenues for research products rose 665 percent to £15.3 million from £2.0 million the year before, while revenues from applied products rose 39 percent to £4.6 million from £3.3 million. Services revenues, meanwhile, fell 24 percent to £5.2 million from £6.8 million in the year-ago period. Revenues from the Dharmacon business grew 5.4 percent year over year to £14.0 million on a pro forma basis.

"I am pleased to report a strong first half performance that saw significant revenue growth due to a robust contribution from the Dharmacon business. We have made a strong start to the second half of the year and, in combination with our sales being second-half weighted, we expect revenues to be slightly ahead of expectations for the year," Horizon CEO Terry Pizzie said in a statement. "I am particularly pleased at the continued development of our major customer relationships, culminating in two new significant agreements already signed in the third quarter in the key growth area of CRISPR screening."

Horizon's net loss for H1 2018 narrowed to £7.6 million, or 5.1 pence per share, from £8.2 million, or 8.6 pence per share, in H1 2017.

Its R&D costs rose 76 percent to £7.4 million in H1 from £4.2 million a year earlier. The firm's sales, marketing, and distribution costs for the period rose 43 percent to £5.7 million from £4.0 million, while its corporate and administrative expenses for H1 2018 rose 31 percent to £9.2 million from £7.0 million in H1 2017.

Horizon ended the first half of the year with £24.9 million in cash and cash equivalents and £1.7 million in investments.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.